Johnson & Johnson’s Janssen COVID-19 vaccine overview and safety

National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.

i

Johnson & Johnson’s Janssen COVID-19 vaccine overview and safety

Supporting Files Public Domain

June 1, 2021
By National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.

File Language:

English

Details

Corporate Authors:

National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
Description:

Updated June 1, 2021 ; Johnson & Johnson’s Janssen COVID-19 Vaccine: CDC and FDA have recommended that use of Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19 Vaccine resume in the United States, effective April 23, 2021. However, women younger than 50 years old especially should be aware of the rare risk of blood clots with low platelets after vaccination, and that other COVID-19 vaccines are available where this risk has not been seen.
Subjects:
Document Type:

Webpage
Corporate as Subject:

Janssen COVID-19 vaccine
Download URL:

https://stacks.cdc.gov/view/cdc/106729/cdc_106729_DS1.pdf
File Type:

[PDF - 145.84 KB]
Collection(s):

Stephen B. Thacker CDC Library
Main Document Checksum:

urn:sha256:f6089b4e0050a4fa8edb67f3937d724810d4c3b9ca06171bae5ebc39106e4544

JJUpdate.html

html

File Language:

English

ON THIS PAGE

Details Supporting Files

Was this page helpful?

Found an issue?

Send us an email at:

publishinghd@cdc.gov

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.